How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
32
ICU Quote, Financials, Valuation and Earnings
Last price:
$2.09
Seasonality move
:
2.29%
Day range:
$1.97 - $2.08
52-week range:
$1.69 - $42.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
74.1K
Avg. volume:
289.3K
1-year change:
-81.88%
Market cap:
$9.1M
Revenue:
--
EPS (TTM):
-$11.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$75K | -- | 120.59% | -- | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$2.03 | -- | $9.1M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.42 | -- | $22.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.54 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.38 | -- | $4.6M | -- | $0.00 | 0% | 1.49x |
|
PTN
Palatin Technologies
|
$0.99 | -- | $19.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.76 | $100.00 | $4.9M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
-- | 0.563 | -- | 0.32x |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$68K | -$4.5M | -- | -- | -6185.29% | -$5M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
SeaStar Medical Holding vs. Competitors
-
Which has Higher Returns ICU or IBIO?
iBio has a net margin of -6585.29% compared to SeaStar Medical Holding's net margin of -4444.57%. SeaStar Medical Holding's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$1.10 -$2.1M IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About ICU or IBIO?
SeaStar Medical Holding has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that SeaStar Medical Holding has higher upside potential than iBio, analysts believe SeaStar Medical Holding is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 IBIOiBio0 0 0 -
Is ICU or IBIO More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock ICU or IBIO?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or IBIO?
SeaStar Medical Holding quarterly revenues are $68K, which are smaller than iBio quarterly revenues of $175K. SeaStar Medical Holding's net income of -$4.5M is lower than iBio's net income of -$4M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $68K -$4.5M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns ICU or NBY?
NovaBay Pharmaceuticals has a net margin of -6585.29% compared to SeaStar Medical Holding's net margin of -49.65%. SeaStar Medical Holding's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$1.10 -$2.1M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About ICU or NBY?
SeaStar Medical Holding has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than SeaStar Medical Holding, analysts believe NovaBay Pharmaceuticals is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is ICU or NBY More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock ICU or NBY?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or NBY?
SeaStar Medical Holding quarterly revenues are $68K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SeaStar Medical Holding's net income of -$4.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $68K -$4.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns ICU or OGEN?
Oragenics has a net margin of -6585.29% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$1.10 -$2.1M OGENOragenics-- -$0.38 -- -
What do Analysts Say About ICU or OGEN?
SeaStar Medical Holding has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23709.52%. Given that Oragenics has higher upside potential than SeaStar Medical Holding, analysts believe Oragenics is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 OGENOragenics0 0 0 -
Is ICU or OGEN More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock ICU or OGEN?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or OGEN?
SeaStar Medical Holding quarterly revenues are $68K, which are larger than Oragenics quarterly revenues of --. SeaStar Medical Holding's net income of -$4.5M is lower than Oragenics's net income of -$2.5M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 1.49x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $68K -$4.5M OGENOragenics1.49x -- -- -$2.5M
-
Which has Higher Returns ICU or PTN?
Palatin Technologies has a net margin of -6585.29% compared to SeaStar Medical Holding's net margin of -2357.27%. SeaStar Medical Holding's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$1.10 -$2.1M PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About ICU or PTN?
SeaStar Medical Holding has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than SeaStar Medical Holding, analysts believe Palatin Technologies is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 PTNPalatin Technologies0 0 0 -
Is ICU or PTN More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock ICU or PTN?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or PTN?
SeaStar Medical Holding quarterly revenues are $68K, which are smaller than Palatin Technologies quarterly revenues of $350K. SeaStar Medical Holding's net income of -$4.5M is higher than Palatin Technologies's net income of -$7.8M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $68K -$4.5M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns ICU or TOVX?
Theriva Biologics has a net margin of -6585.29% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$1.10 -$2.1M TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About ICU or TOVX?
SeaStar Medical Holding has a consensus price target of --, signalling upside risk potential of 244.83%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5042.05%. Given that Theriva Biologics has higher upside potential than SeaStar Medical Holding, analysts believe Theriva Biologics is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 TOVXTheriva Biologics1 0 0 -
Is ICU or TOVX More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock ICU or TOVX?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or TOVX?
SeaStar Medical Holding quarterly revenues are $68K, which are larger than Theriva Biologics quarterly revenues of --. SeaStar Medical Holding's net income of -$4.5M is higher than Theriva Biologics's net income of -$7.7M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $68K -$4.5M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
